Experience the Quality With Free NAPLEX Exam Questions That Helps Candidates Pass

Zidovudine (AZT), a nucleoside reverse transcriptase inhibitor, is linked to bone marrow suppression, anemia, and neutropenia. Efavirenz causes CNS side effects, lamivudine is well-tolerated, and indinavir causes nephrolithiasis. CBC monitoring is required for patients on zidovudine.

Tiotropium and umeclidinium are both LAMAs. Using two agents from the same class offers no benefit but increases risk of side effects like dry mouth, urinary retention, and glaucoma exacerbation. Pharmacists should stop duplication. Adding a SABA (C) is reasonable for rescue but does not address duplication. Steroid taper (D) is unrelated. Best action: discontinue one LAMA and educate team on duplication risk.

Comprehensive and Detailed Explanation (≈180–195 words):

Calculate bolus dose: 80 units/kg × 70 kg = 5600 units. With 10,000 units/mL vials, bolus volume = 5600 ÷ 10,000 = 0.56 mL—but boluses are often given from the vial or a dedicated syringe; the answer choices imply withdrawal in mL and rounding for safety in a larger device. Many institutions dilute the bolus for accurate measurement; however, based strictly on vial concentration, 0.56 mL is correct. Next, infusion: 18 units/kg/hr × 70 kg = 1260 units/hr. The prepared bag concentration is 25,000 units/250 mL = 100 units/mL. Thus, infusion rate = 1260 units/hr ÷ 100 units/mL = 12.6 mL/hr. Among options, the rate 12.6 mL/hr appears with bolus 5.6 mL (likely reflecting a 1,000 units/mL syringe dilution assumption). Given the offered discrete choices, B (5.6 mL; 12.6 mL/hr) best matches correct infusion math and a rounded, practically measurable bolus volume frequently used when the bolus is drawn from a 1,000 units/mL dilution. Always verify institutional heparin protocols and rounding standards to ensure accuracy and patient safety.

Dabigatran commonly causes dyspepsia due to tartaric acid content; switching to a factor Xa inhibitor can improve tolerability while maintaining stroke prevention. With CrCl 30–50 mL/min, both apixaban and rivaroxaban are options; however, apixaban 5 mg BID is standard when dose-reduction criteria (age ≥80, weight ≤60 kg, SCr ≥1.5 mg/dL—need two of three) are not met. The patient does not meet reduction criteria; thus apixaban 5 mg BID is appropriate. Option A treats symptoms but leaves the offending agent in place; persistent GI intolerance often warrants a switch. Option C rivaroxaban would typically be 15 mg daily when CrCl 15–50 mL/min, not 20 mg. Option D lists an incorrect INR target; AF goal is INR 2.0–3.0. Transitioning to apixaban preserves efficacy, aligns with renal function, and often reduces GI side effects.

Antimicrobial stewardship emphasizes using the narrowest effective therapy once cultures are available. De-escalation reduces resistance, adverse effects, and cost. Simply documenting (A) is ineffective. Stopping antibiotics entirely (C) risks undertreatment. Adding more broad agents (D) worsens resistance.